Zhaojin International released a research report, stating that at the American Society of Clinical Oncology (ASCO) annual meeting, the Phase III of SKB264, the core product of Kexing Biological-B (06990), has achieved good efficiency and is expected to be widely used in non-small cell lung cancer (NSCLC). In addition, the strong results of Phase III clinical trials of SKB264 in triple-negative breast cancer will help it obtain approval in mainland China. CMBC International has raised the company's target price from HKD 200.77 to HKD 246.13 and maintained the "buy" rating. It is expected that the company will have losses of RMB 659 million, RMB 786 million, and RMB 726 million from 2024 to 2026.